Adamas Pharmaceuticals
ADMS
ADMS was delisted on the 23rd of November, 2021.
73 hedge funds and large institutions have $146M invested in Adamas Pharmaceuticals in 2021 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 26 increasing their positions, 17 reducing their positions, and 11 closing their positions.
135% more capital invested
Capital invested by funds: $62M → $146M (+$83.8M)
73% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 11
53% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 17
20% more call options, than puts
Call options by funds: $830K | Put options by funds: $689K
12% more funds holding
Funds holding: 65 → 73 (+8)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$26.8M |
| 2 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$13.6M |
| 3 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$11.5M |
| 4 |
Swedbank
Stockholm,
Sweden
|
+$7.75M |
| 5 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$6.97M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$4.01M |
| 2 |
D.E. Shaw & Co
New York
|
-$1.66M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$1.66M |
| 4 |
DAM
Deltec Asset Management
New York
|
-$1.23M |
| 5 |
EIM
Essex Investment Management
Boston,
Massachusetts
|
-$1.2M |
ADMS Hedge Fund Activity: Q1 2021 in Review
73 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Adamas Pharmaceuticals (ADMS) for Q1 2021, worth a combined $146M — up 135% from $62M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new ADMS positions and 11 closed out — a net gain of 8 holders — while 26 added to existing stakes and 17 trimmed.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $26.8M. The largest seller was Morgan Stanley, cutting an estimated $4.01M.
- 73 institutional investors held Adamas Pharmaceuticals (ADMS) as of Q1 2021, up from 65 in Q4 2020.
- Funds reported $146M of Adamas Pharmaceuticals stock for Q1 2021, up 135% quarter-over-quarter.
- 19 funds opened new Adamas Pharmaceuticals positions in Q1 2021 and 11 closed out, a net change of +8 holders.
- The largest Adamas Pharmaceuticals buyer in Q1 2021 was Fidelity Investments, an estimated $26.8M added.
- The largest Adamas Pharmaceuticals seller in Q1 2021 was Morgan Stanley, an estimated $4.01M sold.
Based on aggregated 13F filings for Q1 2021.